King's College London

Research portal

Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression

Research output: Contribution to journalArticle

Standard

Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. / Etzerodt, Anders; Tsalkitzi, Kyriaki; Maniecki, Maciej; Damsky, William; Delfini, Marcello; Baudoin, Elodie; Moulin, Morgane; Bosenberg, Marcus; Graversen, Jonas Heilskov; Auphan-Anezin, Nathalie; Moestrup, Søren Kragh; Lawrence, Toby.

In: The Journal of experimental medicine, Vol. 216, No. 10, 07.10.2019, p. 2394-2411.

Research output: Contribution to journalArticle

Harvard

Etzerodt, A, Tsalkitzi, K, Maniecki, M, Damsky, W, Delfini, M, Baudoin, E, Moulin, M, Bosenberg, M, Graversen, JH, Auphan-Anezin, N, Moestrup, SK & Lawrence, T 2019, 'Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression', The Journal of experimental medicine, vol. 216, no. 10, pp. 2394-2411. https://doi.org/10.1084/jem.20182124

APA

Etzerodt, A., Tsalkitzi, K., Maniecki, M., Damsky, W., Delfini, M., Baudoin, E., ... Lawrence, T. (2019). Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. The Journal of experimental medicine, 216(10), 2394-2411. https://doi.org/10.1084/jem.20182124

Vancouver

Etzerodt A, Tsalkitzi K, Maniecki M, Damsky W, Delfini M, Baudoin E et al. Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. The Journal of experimental medicine. 2019 Oct 7;216(10):2394-2411. https://doi.org/10.1084/jem.20182124

Author

Etzerodt, Anders ; Tsalkitzi, Kyriaki ; Maniecki, Maciej ; Damsky, William ; Delfini, Marcello ; Baudoin, Elodie ; Moulin, Morgane ; Bosenberg, Marcus ; Graversen, Jonas Heilskov ; Auphan-Anezin, Nathalie ; Moestrup, Søren Kragh ; Lawrence, Toby. / Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. In: The Journal of experimental medicine. 2019 ; Vol. 216, No. 10. pp. 2394-2411.

Bibtex Download

@article{1031adff8df14f3686d10ff8224fcb1e,
title = "Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression",
abstract = "Tumor-associated macrophages (TAMs) play critical roles in tumor progression but are also capable of contributing to antitumor immunity. Recent studies have revealed an unprecedented heterogeneity among TAMs in both human cancer and experimental models. Nevertheless, we still understand little about the contribution of different TAM subsets to tumor progression. Here, we demonstrate that CD163-expressing TAMs specifically maintain immune suppression in an experimental model of melanoma that is resistant to anti-PD-1 checkpoint therapy. Specific depletion of the CD163+ macrophages results in a massive infiltration of activated T cells and tumor regression. Importantly, the infiltration of cytotoxic T cells was accompanied by the mobilization of inflammatory monocytes that significantly contributed to tumor regression. Thus, the specific targeting of CD163+ TAMs reeducates the tumor immune microenvironment and promotes both myeloid and T cell-mediated antitumor immunity, illustrating the importance of selective targeting of tumor-associated myeloid cells in a therapeutic context.",
author = "Anders Etzerodt and Kyriaki Tsalkitzi and Maciej Maniecki and William Damsky and Marcello Delfini and Elodie Baudoin and Morgane Moulin and Marcus Bosenberg and Graversen, {Jonas Heilskov} and Nathalie Auphan-Anezin and Moestrup, {S{\o}ren Kragh} and Toby Lawrence",
year = "2019",
month = "10",
day = "7",
doi = "10.1084/jem.20182124",
language = "English",
volume = "216",
pages = "2394--2411",
journal = "The Journal of experimental medicine",
issn = "0022-1007",
number = "10",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression

AU - Etzerodt, Anders

AU - Tsalkitzi, Kyriaki

AU - Maniecki, Maciej

AU - Damsky, William

AU - Delfini, Marcello

AU - Baudoin, Elodie

AU - Moulin, Morgane

AU - Bosenberg, Marcus

AU - Graversen, Jonas Heilskov

AU - Auphan-Anezin, Nathalie

AU - Moestrup, Søren Kragh

AU - Lawrence, Toby

PY - 2019/10/7

Y1 - 2019/10/7

N2 - Tumor-associated macrophages (TAMs) play critical roles in tumor progression but are also capable of contributing to antitumor immunity. Recent studies have revealed an unprecedented heterogeneity among TAMs in both human cancer and experimental models. Nevertheless, we still understand little about the contribution of different TAM subsets to tumor progression. Here, we demonstrate that CD163-expressing TAMs specifically maintain immune suppression in an experimental model of melanoma that is resistant to anti-PD-1 checkpoint therapy. Specific depletion of the CD163+ macrophages results in a massive infiltration of activated T cells and tumor regression. Importantly, the infiltration of cytotoxic T cells was accompanied by the mobilization of inflammatory monocytes that significantly contributed to tumor regression. Thus, the specific targeting of CD163+ TAMs reeducates the tumor immune microenvironment and promotes both myeloid and T cell-mediated antitumor immunity, illustrating the importance of selective targeting of tumor-associated myeloid cells in a therapeutic context.

AB - Tumor-associated macrophages (TAMs) play critical roles in tumor progression but are also capable of contributing to antitumor immunity. Recent studies have revealed an unprecedented heterogeneity among TAMs in both human cancer and experimental models. Nevertheless, we still understand little about the contribution of different TAM subsets to tumor progression. Here, we demonstrate that CD163-expressing TAMs specifically maintain immune suppression in an experimental model of melanoma that is resistant to anti-PD-1 checkpoint therapy. Specific depletion of the CD163+ macrophages results in a massive infiltration of activated T cells and tumor regression. Importantly, the infiltration of cytotoxic T cells was accompanied by the mobilization of inflammatory monocytes that significantly contributed to tumor regression. Thus, the specific targeting of CD163+ TAMs reeducates the tumor immune microenvironment and promotes both myeloid and T cell-mediated antitumor immunity, illustrating the importance of selective targeting of tumor-associated myeloid cells in a therapeutic context.

UR - http://www.scopus.com/inward/record.url?scp=85072992274&partnerID=8YFLogxK

U2 - 10.1084/jem.20182124

DO - 10.1084/jem.20182124

M3 - Article

C2 - 31375534

AN - SCOPUS:85072992274

VL - 216

SP - 2394

EP - 2411

JO - The Journal of experimental medicine

JF - The Journal of experimental medicine

SN - 0022-1007

IS - 10

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454